PAREXEL INTERNATIONAL CLINICAL RESEARCH PRIVATE LIMITED

Harbour BioMed has appointed Yajie Li as Chief Medical Officer to lead clinical development and regulatory strategy for the company's immunology and oncology programs.

Panthera Biopartners, the UK's largest Site Management Organisation, has signed two clinical trial contracts worth over £10 million each with international pharmaceutical companies.

Advarra has integrated its electronic institutional review board (eIRB) system with Study Collaboration software, creating an automated connection between IRB review status and study startup workflows.

• The global clinical trial outsourcing market is projected to grow from $43.1 billion in 2025 to $91.2 billion by 2034, representing a robust CAGR of 7.46% as pharmaceutical companies increasingly rely on CROs to streamline research processes. • Advanced technologies including AI, machine learning, and blockchain are transforming clinical trial management, enhancing efficiency and accelerating drug approvals while creating new opportunities for market participants. • North America dominates the market due to its strong pharmaceutical industry and favorable regulatory environment, while Asia-Pacific is emerging as a high-growth region offering cost advantages and large patient populations.

• Clinical trial sponsors and CROs must establish optimal oversight balance, with experts warning that both excessive and insufficient monitoring can impede trial success and efficiency. • Industry leaders at Veeva's Clinical Operations Outsourcing 2024 Forum stress the importance of early collaboration agreements and transparent communication between sponsors and CROs. • As clinical trials become increasingly complex, particularly in specialized therapies, the need for efficient sponsor oversight becomes more crucial for ensuring trial quality and regulatory compliance.

Parexel's analysis reveals trends in FDA expedited designations for advanced therapies, highlighting Breakthrough Therapy Designation (BTD), Regenerative Medicine Advanced Therapy (RMAT), and Fast Track (FT).

A Feinstein Institutes study demonstrates that culturally tailored telemonitoring interventions significantly improve participation among Hispanic and Latinx communities with type 2 diabetes, reducing HbA1c levels from 8.32% to 7.55%.

The National Institute for Health and Care Research (NIHR) is organizing a webinar on January 30, 2024, to address equality, diversity, and inclusion challenges in clinical trial participation.

South Korea has established itself as a global clinical trial hub, supported by government incentives, modern infrastructure, and streamlined regulatory processes that rank it among the top 15 countries for clinical trials.